In-house with Bayer: ‘Focus on quality early and stay close to inventors’

After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

WIPR debuts Global In-House Elite 2026

26 March 2026 LSIPR sister title launches vetted list celebrating leading in-house counsel who demonstrate exceptional ability in managing their organisation's IP portfolio, legal team, and IP culture.

Europe

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

24 March 2026 The drugmaker’s attempt to extend protection for a fast-growing oestrogen-free contraceptive ran into a landmark EU ruling, with the court not persuaded to read it narrowly.

Europe

EPO reports record patent filings, but pharma and biotech lag

24 March 2026 The European Patent Office’s Technology Dashboard reveals only a slight increase in medtech filings, and drops in biotech and pharma, against an overall healthy backdrop.

More features

Novartis bets $2bn on biologics as Xolair patents fade

WIPR debuts Global In-House Elite 2026

mRNA litigation: Who’s winning, who’s filing, and what’s next

Dechert boosts litigation bench with partner duo

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

EPO reports record patent filings, but pharma and biotech lag

Part II: The race to replace semaglutide heats up

Part I: Ozempic goes generic as Novo’s key patent expires

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

More on this story

Editor's picks

Editor's picks

More features